QC
FATE icon

Quadrature Capital’s Fate Therapeutics FATE Stock Holding History

Quadrature Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,343
Closed -$144K – 1737
2026
Q1 		$144K Sell
120,343
-177,739
-60% -$216K ﹤0.01% 1178
2025
Q4 		$293K Sell
298,082
-79,275
-21% -$95.2K ﹤0.01% 853
2025
Q3 		$475K Buy
+377,357
New +$407K 0.01% 533

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrature Capital's FATE Position: Q2 2026 in Review

Quadrature Capital sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 120,343 shares — an estimated $144K sold.

Quadrature Capital first reported a position in FATE in Q3 2025 and held it in 3 quarters. The position peaked at $475K in Q3 2025. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Quadrature Capital reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 120,343 Fate Therapeutics shares in Q2 2026, an estimated $144K.
  • Quadrature Capital first reported a position in Fate Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrature Capital's Fate Therapeutics position peaked at $475K in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.